Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 1Breast 1

Conditions

Small Cell Lung Carcinoma 25Neoplasms 7Lung Neoplasms 5Sarcoma 4Ovarian Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Neuroendocrine Tumors 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Neoplasm Metastasis 2Mesothelioma 2Desmoplastic Small Round Cell Tumor 2Colorectal Neoplasms 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × PM 01183 × Clear all
NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2 Recruiting
280 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

PharmaMar

Phase 1 Completed
69 enrolled 17 charts
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

PharmaMar

Phase 2 Completed
69 enrolled 28 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡